The chILD Foundation today announced that effective September 1, 2020, Wayne I. Danson has assumed the role as Chairman of the Foundation’s Board of Directors. He has been an active member of the Board since 2016. In his new role, Wayne will leverage his deep experience in corporate and financial management to further advance the […]
Boehringer Ingelheim announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
The Lung Family Reunion is both fun and educational weekend for children, siblings, and families affected by Children’s Interstitial Lung Disease (chILD). chILD specialists and clinicians will be leading informative presentations and engaging discussions. Families will have an opportunity to learn about these complex diseases, while socializing in a fun and welcoming with others on […]
The chILD Foundation is excited to announce that Joe McMonigle as the new Chairperson of the Board. Joe has served in several capacities on the board, including member, treasurer, and vice-chair, over the course of several years. Joe brings a strong, family centered vision to the board. Stay tuned for more updates!
Every year the chILD Foundation participates in Giving Tuesday. This global day of giving recognizes the important roles that non-profit foundations, like the chILD Foundation, play in improving society. We also want this day to recognize those that make our Foundation and the important work we do possible, our donors! Please consider giving to give […]
chILD Foundation board chairman Aaron Knobloch has announced the formation of a Scientific Advisory Committee (SAC) consisting of leading physicians and researchers focusing on chILD disorders. The committee will help guide the board regarding research priorities as well as how to document and share research findings.